You are here

NDA for Anti-Insomnia Candidate Filed With FDA

MARLBOROUGH, Mass., April 2 /PRNewswire-FirstCall/-- Sepracor Inc. (Nasdaq: SEPR - News) today announced that the U.S. Food and Drug Administration (FDA) has filed Sepracor's New Drug Application (NDA) for ESTORRA(TM) brand eszopiclone 2 mg and 3 mg tablets for the treatment of transient and chronic insomnia. ESTORRA was studied in the 3 mg dosage strength for adults and in the 2 mg dosage strength for treatment of the elderly population. Sepracor submitted the ESTORRA NDA to the FDA on January 31, 2003.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile